PMID- 27069129
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20220310
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Apr
TI  - Unfractionated Heparin Selectively Modulates the Expression of CXCL8, CCL2 and 
      CCL5 in Endometrial Carcinoma Cells.
PG  - 1535-44
AB  - BACKGROUND/AIM: This in vitro study analyzed the impact of heparins on expression 
      of chemokines in human endometrial adenocarcinoma cell lines. MATERIALS AND 
      METHODS: Cell lines were incubated with unfractionated heparin (UFH), low 
      molecular weight heparins (LMWH) and fondparinux under hypoxic and normoxic 
      conditions. Chemokine (C-X-C motif) ligand 8 (CXCL8), CC-chemokine ligand 2 
      (CCL2) and CCL5 were detected by enzyme-linked immunosorbent assays and real-time 
      reverse transcriptase-polymerase chain reaction and cell viability by 
      fluorometric assay. RESULTS: Different adenocarcinoma cell lines had distinct 
      patterns of chemokine expression. UFH attenuated the secretion of CXCL8 and CCL2, 
      and enhanced that of CCL5. The observed effects of heparin were in addition to 
      the anti-coagulatory properties of heparin and dependent on molecular size and 
      charge. CONCLUSION: UFH has selective modulating effects on the secretion of 
      CXCL8, CCL2 and CCL5 in different endometrial adenocarcinoma cell lines. 
      Molecular size and charge are relevant for these observed effects. By influencing 
      the expression of these inflammatory mediators and thereby affecting the tumour 
      microenvironment, heparins and related agents might play an essential role in the 
      development of new therapeutic strategies.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Doster, Anne
AU  - Doster A
AD  - Department of Obstetrics and Gynecology, University Hospital of Heidelberg, 
      Heidelberg, Germany.
FAU - Schwarzig, Ulrike
AU  - Schwarzig U
AD  - Department of Obstetrics and Gynecology, University of Greifswald, Greifswald, 
      Germany.
FAU - Zygmunt, Marek
AU  - Zygmunt M
AD  - Department of Obstetrics and Gynecology, University of Greifswald, Greifswald, 
      Germany.
FAU - Rom, Joachim
AU  - Rom J
AD  - Department of Obstetrics and Gynecology, University Hospital of Heidelberg, 
      Heidelberg, Germany.
FAU - Schutz, Florian
AU  - Schutz F
AD  - Department of Obstetrics and Gynecology, University Hospital of Heidelberg, 
      Heidelberg, Germany.
FAU - Fluhr, Herbert
AU  - Fluhr H
AD  - Department of Obstetrics and Gynecology, University Hospital of Heidelberg, 
      Heidelberg, Germany herbert.fluhr@med.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (CXCL8 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Interleukin-8)
RN  - 0 (Polysaccharides)
RN  - 9005-49-6 (Heparin)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Adenocarcinoma/*metabolism
MH  - Cell Line, Tumor
MH  - *Chemokine CCL2/genetics/metabolism
MH  - *Chemokine CCL5/genetics/metabolism
MH  - Endometrial Neoplasms/*metabolism
MH  - Female
MH  - Fondaparinux
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Hypoxia/metabolism
MH  - *Interleukin-8/genetics/metabolism
MH  - Polysaccharides/pharmacology
OTO - NOTNLM
OT  - Heparin
OT  - chemokines
OT  - endometrial adenocarcinoma
OT  - tumour environment
EDAT- 2016/04/14 06:00
MHDA- 2016/08/31 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/01/26 00:00 [received]
PHST- 2016/03/17 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
AID - 36/4/1535 [pii]
PST - ppublish
SO  - Anticancer Res. 2016 Apr;36(4):1535-44.